Quest sees slight revenue decrease in Q3 revenues

By LabPulse.com staff writers

October 22, 2021 -- Quest Diagnostics reported a slight decrease in revenues for the third quarter of the 2021 fiscal year, which ended on September 30.

The company said its third quarter revenue was $2.77 billion, down 0.4% from the same period in 2020. However, company executives are looking toward the future, raising Quest's full-year 2021 outlook to reflect higher than anticipated COVID-19 testing volumes and base business performance.

The company posted net income of $498 million in the most recent period, compared with net income of $491 in the corresponding quarter of 2020.

The company noted that COVID-19 molecular testing volumes increased throughout the summer while its base business continued to deliver volume growth versus 2020 and 2019, showing a rebound in September.

Quest Diagnostics debuts new lab facility in NJ
Quest Diagnostics has finished integrating its Northeast regional operations into a new 25,000-sq-ft, next-generation lab facility in Clifton, NJ.
Quest, Paige to collaborate on AI software for pathology
Quest Diagnostics and Paige plan to collaborate on developing new software that will incorporate artificial intelligence (AI) and digital pathology data...
Grail teams with Quest on blood test for early cancer detection
Cancer diagnostics startup Grail has signed Quest Diagnostics to provide phlebotomy services for its upcoming Galleri multicancer early detection blood...
Quest revenues more than double in Q4
Quest Diagnostics delivered record revenues for its fourth quarter and full year due to high demand for COVID-19 testing.
Quest wins CDC contract to sequence COVID-19 gene variants
Quest Diagnostics has received a contract from the U.S. Centers for Disease Control and Prevention (CDC) to provide genomic sequencing for a project aimed...

Copyright © 2021 LabPulse.com

Last Updated ls 10/22/2021 11:13:08 AM



Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current